Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Threshold for respondents to initiate bevacizumab for HOCF based on clinical scenario. CO, cardiac output; CI, cardiac index; NT-proBNP, N-terminal pro-brain natriuretic peptide

From: Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

Clinical ScenarioWould Initiate BevacizumabWould Not Initiate Bevacizumab
Elevated CO/CI, normal NT-proBNP
Moderate left atrial enlargement, no arrhythmias
No signs or symptoms of HF or activity restriction
11%89%
Elevated CO/CI, elevated NT-proBNP
Moderate left atrial enlargement, no arrhythmias
No signs or symptoms of HF or activity restriction
11%89%
Elevated CO/CI, elevated NT-proBNP
Severe left atrial enlargement, no arrhythmias
No signs or symptoms of HF or activity restriction
26%74%
Elevated CO/CI, elevated NT-proBNP
Severe left atrial enlargement, paroxysmal atrial fibrillation
No signs or symptoms of HF or activity restriction
63%37%
Elevated CO/CI, elevated NT-proBNP
Severe left atrial enlargement, paroxysmal atrial fibrillation
Mild dyspnea on exertion, exercise limitation
79%21%